Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E20.44 EPS (ttm)1.83 Insider Own0.10% Shs Outstand5.90B Perf Week-0.53%
Market Cap220.29B Forward P/E12.16 EPS next Y3.07 Insider Trans-14.28% Shs Float5.85B Perf Month2.39%
Income11.05B PEG3.13 EPS next Q0.74 Inst Own73.20% Short Float1.01% Perf Quarter1.91%
Sales52.67B P/S4.18 EPS this Y49.80% Inst Trans0.16% Short Ratio2.87 Perf Half Y1.06%
Book/sh11.78 P/B3.17 EPS next Y4.07% ROA12.80% Target Price39.80 Perf Year11.30%
Cash/sh1.94 P/C19.29 EPS next 5Y6.53% ROE33.40% 52W Range32.32 - 39.43 Perf YTD3.06%
Dividend1.36 P/FCF30.47 EPS past 5Y7.90% ROI9.90% 52W High-5.33% Beta0.91
Dividend %3.64% Quick Ratio1.00 Sales past 5Y-0.80% Gross Margin79.20% 52W Low15.50% ATR0.35
Employees90200 Current Ratio1.30 Sales Q/Q1.00% Oper. Margin24.80% RSI (14)61.00 Volatility0.71% 0.86%
OptionableYes Debt/Eq0.58 EPS Q/Q14.80% Profit Margin41.30% Rel Volume0.72 Prev Close37.36
ShortableYes LT Debt/Eq0.45 EarningsJul 31 BMO Payout35.60% Avg Volume20.60M Price37.33
Recom2.60 SMA201.17% SMA502.68% SMA2003.30% Volume14,736,295 Change-0.08%
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jul-22-18 10:41PM  [$$] The Chinese Blind Spot in U.S. Companies Financials The Wall Street Journal
Jul-21-18 12:00PM  4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio TheStreet.com
Jul-20-18 09:04PM  Pharmaceutical Companies Seek Stability in Trump Drug Cost Fight Bloomberg
05:43PM  Pfizer gets FDA approval for drug similar to Amgen's Neupogen MarketWatch
04:52PM  GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant TheStreet.com
04:24PM  U.S. FDA Approves Pfizers Biosimilar NIVESTYM (filgrastim-aafi) Business Wire
03:08PM  Merck reduced prices of small and insignificant drugs: An... CNBC Videos
02:02PM  [$$] Big Bet on Pfizer for a Market-Beating Investment Firm Barrons.com
01:59PM  Swiss, German drugmakers join U.S. price freeze Reuters
01:38PM  Roche Takes Drug-Price Posturing to New Heights Bloomberg
11:49AM  Merck Announces Plans To Cut Drug Prices Benzinga
11:11AM  Swiss, German drugmakers join U.S. price freeze Reuters
10:07AM  Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy Zacks
09:21AM  3 Stocks That Could Be Added to the Dow Next Motley Fool
08:59AM  Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals Zacks
07:30AM  Three Key Takeaways From Healthcare Earnings Season TheStreet.com
Jul-19-18 10:49PM  [$$] Merck to Limit Drug-Price Increases, Cut Some Prices The Wall Street Journal
06:13PM  Merck lowers prices of some drugs after Trump calls out industry Reuters
06:02PM  [$$] Merck to Limit Drug-Price Increases, Cut Some Prices The Wall Street Journal
05:22PM  Merck lowers prices of some drugs after Trump calls out industry Reuters
10:14AM  AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short' MarketWatch
09:28AM  Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study Zacks
07:29AM  Better Buy: Novavax, Inc. vs. Pfizer Motley Fool
06:52AM  Trump thanks Novartis, Pfizer for not raising drug prices Reuters
Jul-18-18 08:00PM  [$$] Novartis Wont Raise U.S. Drug Prices This Year The Wall Street Journal
03:26PM  Pfizer, Eli Lilly non-opioid pain drug nears finish line MarketWatch
03:07PM  5 Big Biotech Stories to Watch TheStreet.com
12:51PM  Novartis hints at 2018 outlook hike despite drug price freeze Reuters
10:50AM  [$$] Novartis Won't Raise U.S. Drug Prices This Year The Wall Street Journal
08:51AM  Pfizer-Lilly pain drug meets late-stage trial goals Reuters
08:49AM  Pfizer-Lilly pain drug meets late-stage trial goals Reuters
08:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Hikma raising injectable opioids output to help ease shortage at U.S. hospitals Reuters
06:57AM  Pfizer-Lilly pain drug found effective in late-stage study Reuters
06:53AM  Novartis joins Pfizer in halting U.S. drug price hikes Reuters
06:45AM  Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain Business Wire
02:36AM  Novartis Joins Pfizer in Holding Line on Drug Prices in U.S. Bloomberg
02:36AM  Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year Bloomberg
Jul-17-18 03:15PM  Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III Zacks
11:33AM  TD Ameritrade: Setting Time Target Best Way for Investors to Ignore Noise Investopedia
10:30AM  Johnson & Johnson CEO defends drug prices, calls for changes in how medical costs are covered CNBC
09:53AM  How Johnson & Johnson Became A Household Name Investopedia
Jul-16-18 06:50PM  Increasing drug prices despite public scrutiny 'makes absolutely no sense,' says analyst CNBC
04:16PM  Pfizer begins late-stage testing of Spark's hemophilia B gene therapy American City Business Journals
04:10PM  UAB researchers make big discovery on diabetes research American City Business Journals
02:34PM  Drugmakers will think twice on price increases after Trum... CNBC Videos
12:44PM  Analysis: Motivating Factors Behind Pfizers Big Split Investopedia
10:31AM  Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy Business Wire
09:32AM  Pfizer's Reorganizing Again. Is Its Stock a Buy Now? Motley Fool
08:31AM  Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population Zacks
07:21AM  With General Electric Gone, Which Dow Component Will Be Kicked Out Next? Motley Fool
Jul-15-18 07:50PM  [$$] This Form of Ambien Now Costs Over 800% More The Wall Street Journal
Jul-14-18 09:00AM  [$$] Drugmaker Raises Price of Sleep Aid Over 800% The Wall Street Journal
Jul-13-18 03:09PM  Novartis Looks to Exit Antibacterial, Antiviral Program Zacks
02:30PM  U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC) PR Newswire
02:30PM  U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC) Business Wire
10:19AM  7 Hot Stocks Savvy Investors Are Buying InvestorPlace
09:47AM  5 Big Pharma Stocks Investors Love Right Now InvestorPlace
08:50AM  Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit Zacks
08:34AM  Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize Zacks
12:15AM  [$$] Pfizer boss humbled after man to man talk with Donald Trump Financial Times
Jul-12-18 10:11AM  3 Real Risks That Could Make You Reconsider Buying Celgene Stock InvestorPlace
09:35AM  Pfizer (PFE) to Reorganize Business Into Three New Units Zacks
09:30AM  Is Pfizer (PFE) Outperforming Other Medical Stocks This Year? Zacks
09:08AM  Your first trade for Thursday, July 12 CNBC
08:59AM  3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018 Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Achieve Life Sciences and Pfizer ACCESSWIRE
02:00AM  [$$] The drug pricing playbook: how pharma companies keep costs high Financial Times
12:37AM  [$$] Pfizer to Reorganize Business Units The Wall Street Journal
12:15AM  [$$] Battle erupts between Fox and Comcast for UKs Sky Financial Times
12:00AM  Many Drugmakers Ignore Trumpand Raise Prices Anyway Bloomberg
Jul-11-18 08:00PM  Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI TheStreet.com
06:10PM  REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization TheStreet.com
05:54PM  Pfizer's China Exposure Could Dampen Its Reshuffle Hopes TheStreet.com
05:07PM  Pfizer separates consumer health unit in business rejig Reuters
04:25PM  Pfizer's Reorganization Into 3 Businesses Seeks to Unlock Value TheStreet.com
04:24PM  Pfizer: Why This Blue-Chip Dividend Stock Is a Buy Today TheStreet.com
04:03PM  Dow Slumps on Trump Trade War Escalation TheStreet.com
04:01PM  4 Things You Need to Know About Pfizer's Restructuring Plans Motley Fool
04:00PM  Dying to Survive, China Shows the Way on Drug Prices Bloomberg
03:56PM  [$$] Investors Should Be Worried About Pfizer's Reversal Barrons.com
03:31PM  Trump told Pfizer CEO price hikes hurt his drug plan: source Reuters
03:11PM  Russian Drugmaker Granted License to Produce Celgene Copycat Fortune
02:41PM  Pfizer to split into three units Reuters Videos
02:01PM  The Midday Rundown: July 11, 2018 CNBC Videos
01:50PM  3 Key Lessons From Trumps Drug Price Feud With Pfizer Fortune
12:35PM  Pfizer Separates Consumer Health Care Unit Benzinga
12:12PM  Pfizer Is Not at a Buy Point, but Here's an Options Play on the Name TheStreet.com
12:10PM  Pfizer Reorganization Could Set the Stage for Full-Blown Spin-off TheStreet.com
12:10PM  Pfizer Reorganization Could Set the Stage for Full-Blown Spinoff TheStreet.com
11:32AM  Trump told Pfizer CEO price hikes hurt his drug plan: source Reuters
11:13AM  Jim Cramer Reacts to Pfizer's Reorganization TheStreet.com
11:03AM  Cramer sees Pfizer's reorganization as a 'prelude' to a spin off of its consumer health-care business CNBC
10:52AM  Pfizer Doesn't Look Fundamentally or Technically Strong TheStreet.com
10:22AM  Trump Said He Got Pfizer to Roll Back Prices. Not Really. Bloomberg
10:15AM  Pfizer Caving to Trump Has Wall Street Worried About Who's Next Bloomberg
09:56AM  Pfizer to Reorganize Itself Into 3 Business Units TheStreet.com
09:51AM  How Companies Navigate Trump's Tweets, Trade Tariffs Bloomberg Video
09:23AM  Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie The Wall Street Journal
09:07AM  Pfizer to split into three units, separates consumer healthcare Reuters
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
READ IAN CChairman & CEOJul 16Sale37.36486,75318,186,315659,440Jul 17 04:59 PM
OLSON LAURIE JExecutive Vice PresidentJun 06Sale36.4519,000692,58282,886Jun 08 01:11 PM
CORNWELL W DONDirectorJun 04Sale36.405,223190,1170Jun 05 04:44 PM
READ IAN CChairman & CEOMay 01Sale36.01132,3124,764,0811,144,703May 03 04:19 PM
JOHNSON RADY AExecutive Vice PresidentMar 13Sale36.5527,323998,66643,178Mar 14 05:19 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 13Sale36.8950,0001,844,39883,857Mar 14 05:13 PM
Dolsten MikaelPresident R&DMar 09Sale36.5969,6992,550,39451,185Mar 12 05:01 PM
HILL CHARLES HExecutive Vice PresidentMar 06Sale35.7642,3931,515,98557,328Mar 07 04:09 PM
Dolsten MikaelPresident R&DMar 02Sale35.8513,986501,398120,884Mar 05 09:23 AM
HILL CHARLES HExecutive Vice PresidentFeb 28Option Exercise27.37101,8722,788,237207,942Mar 02 03:24 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37121,1453,315,739362,707Mar 02 04:10 PM
OLSON LAURIE JExecutive Vice PresidentFeb 28Option Exercise27.3738,5461,055,004132,702Mar 02 04:02 PM
READ IAN CChairman & CEOFeb 28Option Exercise27.37649,78017,784,4791,774,184Mar 02 04:03 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.37110,1323,014,313245,362Mar 02 04:03 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50239,801Mar 02 03:44 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50285,910Mar 02 03:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3746,8061,281,080171,276Mar 02 03:44 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 28Option Exercise27.37104,6262,863,614384,219Mar 02 03:44 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37209,2515,727,200655,161Mar 02 03:24 PM
BOURLA ALBERTChief Operating OfficerFeb 28Option Exercise27.3739,9231,092,693184,120Mar 02 03:24 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3733,040904,305136,847Mar 02 03:24 PM
Dolsten MikaelPresident R&DFeb 28Option Exercise27.37198,2385,425,774293,352Mar 02 03:24 PM
HILL CHARLES HExecutive Vice PresidentFeb 28Sale36.8326,779986,292181,163Mar 02 03:24 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Sale37.0333,3681,235,591135,230Feb 28 06:14 PM
Dolsten MikaelPresident R&DFeb 27Sale37.0464,5872,392,31395,114Feb 28 06:04 PM
CORNWELL W DONDirectorFeb 27Sale37.0530011,1150Feb 28 01:29 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 26Sale37.199,510353,67717,770Feb 27 07:38 PM
CORNWELL W DONDirectorFeb 26Sale36.741,45853,5640Feb 28 01:29 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9043,520822,528223,733Feb 27 08:59 PM
READ IAN CChairman & CEOFeb 24Option Exercise19.83903,55917,917,2651,560,007Feb 27 08:58 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9015,716297,03290,222Feb 27 07:53 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456206,972Feb 27 07:51 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9015,885300,22762,848Feb 27 07:43 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9028,288534,643112,081Feb 27 07:43 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456313,499Feb 27 07:43 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 24Option Exercise18.9015,957301,58736,959Feb 27 07:38 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 24Option Exercise18.9039,555747,590143,152Feb 27 07:38 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9065,2801,233,792122,609Feb 27 07:38 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90174,0813,290,131225,265Feb 27 07:32 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9028,288534,643116,769Feb 27 07:30 PM
BOURLA ALBERTChief Operating OfficerFeb 24Option Exercise18.9025,387479,814158,170Feb 27 07:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90174,0813,290,131511,470Feb 27 07:30 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 15Sale37.006,750249,750103,458Dec 18 06:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 15Sale37.078,000296,56046,963Dec 18 06:17 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentNov 01Sale34.947,350256,809110,082Nov 02 07:03 PM
PFIZER INC10% OwnerOct 10Buy17.0040,000680,0001,427,639Oct 10 04:22 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentOct 02Sale35.657,350262,028117,432Nov 02 07:03 PM
SUSMAN SALLYExecutive Vice PresidentSep 12Sale35.0038,2301,338,050115,096Sep 14 09:13 AM
MACKENZIE ALEXANDER RExecutive Vice PresidentSep 01Sale34.007,350249,900124,774Sep 05 06:15 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 31Sale34.007,350249,900132,124Sep 01 06:37 PM
DAMELIO FRANK AExecutive Vice PresidentAug 31Sale34.0094,4093,209,906337,389Sep 01 06:37 PM
READ IAN CChairman & CEOAug 31Sale34.00141,1934,800,56280,762Sep 01 06:37 PM
READ IAN CChairman & CEOAug 31Sale34.0055,9751,903,150580,318Sep 01 06:37 PM
OLSON LAURIE JExecutive Vice PresidentAug 21Sale32.708,064263,69374,506Aug 23 03:51 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 07Sale33.5015,000502,560139,474Aug 09 05:00 PM
READ IAN CChairman & CEOAug 04Sale34.0068,8342,340,356221,955Aug 08 05:02 PM
READ IAN CChairman & CEOAug 04Sale34.0028,116955,944636,293Aug 08 05:02 PM